<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749202</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-10001</org_study_id>
    <nct_id>NCT01749202</nct_id>
  </id_info>
  <brief_title>Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solae, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Solae, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of stearidonic acid when used as a food
      ingredient on eicosapentaenoic enrichment of red blood cell membranes and Omega-3 Index in
      men and women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End of treatment EPA level in RBC membranes, expressed as a percent of total RBC membrane fatty acids</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Omega-3 Index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDA percent of total RBC membrane fatty acids</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA (IR) and HOMA (%B)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Sudden Cardiac Death</condition>
  <condition>Sudden Cardiac Arrest</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sunflower Oil Softgels</intervention_name>
    <description>3 x 500 mg softgel capsules/day</description>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA softgels</intervention_name>
    <description>3 x 500 mg softgel capsules/day</description>
    <arm_group_label>Positive Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunflower Oil Food</intervention_name>
    <description>3 servings/day</description>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_label>Positive Control</arm_group_label>
    <other_name>Food</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SDA soybean Oil Food</intervention_name>
    <description>3 servings/day</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Food</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 21 to 65 years of age.

          2. BMI) ≥18.00 and &lt;40.00 kg/m2.

          3. No health conditions that would prevent him/her from fulfilling the study requirements
             as judged by the Investigator on the basis of medical history and routine laboratory
             test results.

          4. Willing to avoid alcohol consumption for 24 h prior to every clinic visit.

          5. No plans to change smoking habits during the study period.

          6. Willing to maintain a stable body weight, activity level and dietary pattern except
             for use of the study products, as directed.

          7. Understands the study procedures and signs forms providing informed consent to
             participate in the study and authorization for release of relevant protected health
             information to the study Investigator.

        Exclusion Criteria:

          1. Subject has coronary heart disease or a coronary heart disease risk equivalent
             including any of the following:

               -  Diabetes mellitus

               -  Clinical signs of atherosclerosis including peripheral arterial disease,
                  abdominal aortic aneurysm, carotid artery disease

               -  Presence of multiple risk factors that give a person a greater than 20% chance
                  for developing coronary artery disease within 10 years.

          2. Abnormal laboratory test results of clinical significance

          3. TG ≥400 mg/dL at visit 1, week -2.

          4. Smokes more than one pack of cigarettes (20 cigarettes) per day.

          5. History or presence of clinically important renal, hepatic, pulmonary, biliary,
             gastrointestinal, neurologic or endocrine disorders that in the judgment of the
             Investigator, would interfere with the subject's ability to provide informed consent,
             comply with the study protocol Stable, treated hypothyroidism is allowed.

          6. Uncontrolled hypertension

          7. Unstable use within four weeks of visit 1 (week -2) of antihypertensive medications or
             thyroid hormone replacement.

          8. Use of any lipid-altering drugs, including statins, bile acid sequestrants,
             cholesterol absorption inhibitors, fibrates, or prescription formulations of niacin
             within four weeks of visit 1 (week -2) and throughout the study. If a subject needs to
             wash off of a drug, he/she will be consented and then asked to return after the four
             week washout.

          9. Use of EPA/DHA from a drug or supplement within four months of visit 1

         10. Frequent use (more than twice per month) of any non-study-related EPA/DHA containing
             enriched foods (such as DHA-enriched eggs) within four months of visit 1, week -2 and
             avoidance of these enriched foods throughout the study period

         11. Use of seeds and oils containing a significant amount of ALA

         12. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, or sardines) more
             than twice per month

         13. Use of any dietary supplement known to alter lipid metabolism

         14. Use of any weight-loss medication

         15. Use of any weight loss supplement or program within four weeks of visit 1

         16. Known allergy or sensitivity to study products or any ingredients of the study
             products.

         17. Subject is unwilling to consume the study products (bars, beverages and capsules)
             based on results from the taste testing of the study products at visit 1, week -2.

         18. Subject has a history or presence of cancer in the prior two years, except for
             non-melanoma skin cancer

         19. Females who are pregnant, planning to be pregnant during the study period, lactating,
             or women of childbearing potential who are unwilling to commit to the use of a
             medically approved form of contraception throughout the study period. The method of
             contraception must be recorded in the source documentation.

         20. Current or recent history of (within 12 months of visit 1, week -2) or strong
             potential for alcohol or substance abuse. Alcohol abuse will be defined as &gt;14 drinks
             per week (1 drink = 12 oz beer, 5 oz wine, or 1 ½ oz distilled spirits).

         21. Exposure to any non-registered drug product within 30 days prior to the screening
             visit (visit 1, week -2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ratna Mukherjea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Solae, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Provident Clinical Research &amp;Consulting</name>
      <address>
        <city>Glen Ellyn</city>
        <state>Illinois</state>
        <zip>60137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega 3 fatty acids</keyword>
  <keyword>Omega 3 Index</keyword>
  <keyword>Stearidonic acid (SDA)</keyword>
  <keyword>Red Blood Cells</keyword>
  <keyword>Lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

